The Current Opioid Misuse Measure (COMM), a self-report assessment of past-month aberrant medication-related behaviors, has been validated in specialty pain management patients. The performance characteristics of the COMM were evaluated in primary care (PC) patients with chronic pain. It was hypothesized that the COMM could identify patients with prescription drug use disorder (PDD). English-speaking adults awaiting PC visits at an urban, safety-net hospital, who had chronic pain and had received any opioid analgesic prescription in the past year, were administered the COMM. The Composite International Diagnostic Interview served as the ''gold standard,'' using DSM-IV criteria for PDD and other substance use disorders (SUDs). A receiver operating characteristic (ROC) curve demonstrated the COMM's diagnostic test characteristics. Of the 238 participants, 27 (11%) met DSM-IV PDD criteria, whereas 17 (7%) had other SUDs, and 194 (82%) had no disorder. The mean COMM score was higher in those with PDD than among all others (ie, those with other SUDs or no disorder, mean 20.4 [SD 10.8] vs 8.4 [SD 7.5], P < .0001). A COMM score of P13 had a sensitivity of 77% and a specificity of 77% for identifying patients with PDD. The area under the ROC curve was 0.84. For chronic pain patients prescribed opioids, the development of PDD is an undesirable complication. Among PC patients with chronic painprescribed prescription opioids, the COMM is a promising tool for identifying those with PDD. Ó
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Introduction
Multiple studies have shown dramatic increases in prescriptions for opioid analgesics for chronic non-cancer chronic pain in the United States [12, 25, 31] . Although more Americans use marijuana for pain relief, the number of first time abusers of prescription pain medications has recently exceeded the number of new marijuana users [1] . With the initial diagnosis and management of chronic, non-cancer pain falling largely under the domain of the primary care physician (PCP), many of these doctors report they are not adequately trained to recognize and manage patients at high-risk for, or experiencing, prescription drug use disorder (PDD) [6] . Experts in addiction and pain debate what constitutes PDD in a chronic pain population [15, 30] . Although there is some consensus regarding clinical features that patients with PDD typically exhibit, no single ''gold standard'' exists for diagnosing PDD in primary care (PC) patients with chronic pain [2,4,5,9,29].
Current practice guidelines recommend using the Current Opioid Misuse Measure (COMM) to assess patients who are prescribed opioid therapy [7] . Developed by experts in pain and addiction, the COMM is a patient self-report assessment of past-month aberrant medication-related behaviors, defined as behaviors that are concerning for addiction or taking a medication in a way other than how it is prescribed [5, 27] . Aberrant medication-related behaviors may include PDD as well as unintentional misuse, purposeful diversion, or addiction to substances other than pain medication. The COMM validation study was conducted with patients treated in specialty pain management clinics, and a score of 9 or greater was determined to be suggestive of prior 30-day prescription opioid misuse.
The diagnostic capabilities of the COMM have not been evaluated among PC patient populations. Diagnostic tests may perform differently when used in clinical settings other than those in which
